Arkwright 2001 |
United Kingdom |
41 (21, 20) |
5 – 18 y |
MV3
(Heat-killed Mycobacterium vaccae SRL 172) |
0.3 mL |
Intradermal |
3 mo |
Placebo |
SASSAD index, adverse events |
1, 3 mo |
Arkwright 2003 |
United Kingdom |
56 (29, 27) |
2 – 6 y |
MV1
(Heat-killed Mycobacterium vaccae SRP 299) |
10 mg/mL |
Intradermal |
6 mo |
Placebo |
SASSAD index, adverse
events§
|
1, 3, 6 mo |
Berth-Jones 2006
|
United Kingdom, Croatia
|
101 (52, 49)
|
5 – 16 y
|
High dose MV1 (Heat-killed Mycobacterium vaccae SRP
299) †
Low dose (Heat-killed Mycobacterium vaccae SRP 299)
|
1 mg
0.1
mg
|
Intradermal
|
12 wk
|
Placebo
|
SASSAD index, adverse events‡
|
12, 24 wk
|
|
Bodemer 2017 |
France |
179 (93, 86) |
6 months – 7 years |
Mix
(Lyophilized Haemophilus influenzae, Streptococcus pneumoniae, S.
aureus, S. viridans, S. pyogenes, Klebsiella ozaenae, K. pneumoniae,
Neisseria catarrhalis) |
3.5 mg |
Oral |
9 mo |
Placebo |
Adverse
events†
|
1, 3, 6, 9 months |
Brothers 2009 |
New Zealand |
124 (61, 63) |
5 – 16 years |
MV2
(Heat-killed Mycobacterium vaccae AVAC) |
250 µg/mL |
Intradermal |
6 wk |
Placebo |
SASSAD index, adverse events |
3, 6
months |
D’Auria 2020 |
Italy |
58 (29, 29) |
6 – 36 mo |
LP1 (Heat-killed
Lactobacillus paracasei CBA L74) |
8 g |
Oral |
12 wk |
Placebo |
SCORAD index |
4, 8, 12 weeks |
Jeong 2020 |
South Korea |
66 (33, 33) |
1 – 12 years |
LR (Tyndallized
Lactobacillus rhamnosus IDCC 3201) |
1010
CFU/day |
Oral |
12 wk |
Placebo |
SCORAD index, adverse events |
6, 12
weeks |
|
|
Rather 2021 |
South Korea |
42 (22, 20) |
3 – 18 years |
LS
(Heat-killed Lactobacillus sakei proBio65) |
400 mg |
Oral |
12
wk |
Placebo |
SCORAD index, adverse events |
6, 12 weeks |
Yan 2019 |
Taiwan |
126 (64, 62) |
4 – 30 months |
LP2 (Heat-treated
Lactobacillus paracasei GM-080) |
1010 CFU/day |
Oral |
16 wk |
Placebo |
SCORAD index, adverse
events†
|
4, 10, 16 weeks |